Prelude Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-124,788
Closed -$22.9M 2356
2021
Q2
$22.9M Buy
124,788
+78,136
+167% +$13.4M 1.27% 14
2021
Q1
$7.13M Buy
46,652
+36,752
+371% +$5.69M 0.5% 70
2020
Q4
$1.55M Buy
9,900
+5,222
+112% +$671K 0.12% 364
2020
Q3
$535K Sell
4,678
-6,496
-58% -$701K 0.07% 429
2020
Q2
$1.25M Buy
11,174
+10,848
+3,328% +$1.15M 0.2% 262
2020
Q1
$29K Sell
326
-2,247
-87% -$221K 0.01% 895
2019
Q4
$278K Buy
2,573
+1,864
+263% +$199K 0.04% 750
2019
Q3
$69K Sell
709
-11,134
-94% -$1.26M 0.01% 1070
2019
Q2
$1.55M Buy
+11,843
New +$1.53M 0.15% 246
2019
Q1
Sell
-124
Closed -$15.4K 2466
2018
Q4
$12K Buy
+124
New +$14.7K ﹤0.01% 1350
2018
Q3
Sell
-3,894
Closed -$483K 2264
2018
Q2
$483K Buy
+3,894
New +$455K 0.04% 543
2018
Q1
Sell
-7,683
Closed -$918K 1864
2017
Q4
$919K Buy
+7,683
New +$936K 0.09% 274
2017
Q3
Sell
-12,470
Closed -$1.52M 2056
2017
Q2
$1.52M Buy
12,470
+9,312
+295% +$1.08M 0.16% 147
2017
Q1
$383K Buy
3,158
+2,755
+684% +$355K 0.05% 372
2016
Q4
$49K Buy
+403
New +$49.3K 0.01% 1052
2016
Q2
Sell
-775
Closed -$108K 1848
2016
Q1
$108K Sell
775
-4,482
-85% -$658K 0.02% 744
2015
Q4
$1M Buy
5,257
+636
+14% +$111K 0.18% 157
2015
Q3
$723K Buy
4,621
+186
+4% +$33.9K 0.12% 224
2015
Q2
$802K Sell
4,435
-901
-17% -$155K 0.12% 211
2015
Q1
$925K Buy
5,336
+3,441
+182% +$623K 0.13% 194
2014
Q4
$351K Sell
1,895
-200
-10% -$37.1K 0.06% 426
2014
Q3
$347K Buy
2,095
+328
+19% +$53.9K 0.05% 509
2014
Q2
$276K Sell
1,767
-3,381
-66% -$534K 0.05% 609
2014
Q1
$783K Buy
5,148
+1,176
+30% +$187K 0.13% 252
2013
Q4
$528K Hold
3,972
0.1% 337
2013
Q3
$461K Sell
3,972
-6,000
-60% -$658K 0.11% 317
2013
Q2
$920K Buy
+9,972
New +$961K 0.26% 117

Other funds holding ALXN